![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
U. S. Food and Drug Administration–National Cancer Institute Clinical Proteomics Program, * Office of the Director, Center for Biologic Evaluation and Research, U. S. Food and Drug Administration, Rockville, MD 20852 and Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
2 To whom correspondence should be addressed. E-mail: petricoin{at}cber.fda.gov.
Proteomics, the systematic evaluation of changes in the protein constituency of a cell, is more than just the generation of lists of proteins that increase or decrease in expression as a cause or consequence of disease. The ultimate goal is to characterize the information flow through protein pathways that interconnect the extracellular microenvironment with the control of gene transcription. The nature of this information can be a cause or a consequence of disease processes. Clinical applications of proteomics involve the use of proteomic technologies at the bedside. The analysis of human cancer as a model for how proteomics can have an impact at the bedside is now employing several new proteomic technologies that are being developed for early detection, therapeutic targeting and finally, patient-tailored therapy.
KEY WORDS: • proteomics • pattern diagnostics • SELDI • protein microarrays • cell signaling
This article has been cited by other articles:
|
|
 |
|
  V. Kulasingam and E. P. Diamandis Proteomics Analysis of Conditioned Media from Three Breast Cancer Cell Lines: A Mine for Biomarkers and Therapeutic Targets Mol. Cell. Proteomics, November 1, 2007; 6(11): 1997 - 2011. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. B. Bach, G. A. Silvestri, M. Hanger, and J. R. Jett Screening for Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 69S - 77S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. D. Vo and B. O. Palsson Building the power house: recent advances in mitochondrial studies through proteomics and systems biology Am J Physiol Cell Physiol, January 1, 2007; 292(1): C164 - C177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Shankar, N. Gude, F. Cullinane, S. Brennecke, A. W Purcell, and E. K Moses An emerging role for comprehensive proteome analysis in human pregnancy research Reproduction, June 1, 2005; 129(6): 685 - 696. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. S. Swanson, M. J. Mazur, K. Vashisht, L. A. Rund, J. E. Beever, C. M. Counter, and L. B. Schook Genomics and Clinical Medicine: Rationale for Creating and Effectively Evaluating Animal Models Experimental Biology and Medicine, October 1, 2004; 229(9): 866 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Radulovic, S. Jelveh, S. Ryu, T. G. Hamilton, E. Foss, Y. Mao, and A. Emili Informatics Platform for Global Proteomic Profiling and Biomarker Discovery Using Liquid Chromatography-Tandem Mass Spectrometry Mol. Cell. Proteomics, October 1, 2004; 3(10): 984 - 997. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Moschos, J. M. Kirkwood, and P. A. Konstantinopoulos Present Status and Future Prospects for Adjuvant Therapy of Melanoma: Time to Build upon the Foundation of High-dose Interferon Alfa-2b J. Clin. Oncol., January 1, 2004; 22(1): 11 - 14. [Full Text] [PDF]
|
|
|
|
 |
|
 V. L. W. Go, R. R. Butrum, and D. A. Wong Diet, Nutrition, and Cancer Prevention: The Postgenomic Era J. Nutr., November 1, 2003; 133(11): 3830S - 3836. [Abstract] [Full Text] [PDF]
|
|
